Literature DB >> 26440741

Preclinical combination of TP-0903, an AXL inhibitor and B-PAC-1, a procaspase-activating compound with ibrutinib in chronic lymphocytic leukemia.

Viralkumar Patel1, Michael J Keating2, William G Wierda2, Varsha Gandhi1,2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26440741      PMCID： PMC4963009          DOI： 10.3109/10428194.2015.1102243

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN： 1026-8022


× No keyword cloud information.
  14 in total

1.  Ibrutinib in relapsed chronic lymphocytic leukemia.

Authors:  John C Byrd; Susan O'Brien; Danelle F James
Journal:  N Engl J Med       Date:  2013-09-26       Impact factor: 91.245

2.  First Axl inhibitor enters clinical trials.

Authors:  Cormac Sheridan
Journal:  Nat Biotechnol       Date:  2013-09       Impact factor: 54.908

3.  Proteasome inhibitor carfilzomib complements ibrutinib's action in chronic lymphocytic leukemia.

Authors:  Betty Lamothe; Fabiola Cervantes-Gomez; Mariela Sivina; William G Wierda; Michael J Keating; Varsha Gandhi
Journal:  Blood       Date:  2015-01-08       Impact factor: 22.113

4.  Small-molecule activation of procaspase-3 to caspase-3 as a personalized anticancer strategy.

Authors:  Karson S Putt; Grace W Chen; Jennifer M Pearson; Joseph S Sandhorst; Martin S Hoagland; Jung-Taek Kwon; Soon-Kyung Hwang; Hua Jin; Mona I Churchwell; Myung-Haing Cho; Daniel R Doerge; William G Helferich; Paul J Hergenrother
Journal:  Nat Chem Biol       Date:  2006-08-27       Impact factor: 15.040

5.  Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy.

Authors:  Jennifer A Woyach; Kelly Smucker; Lisa L Smith; Arletta Lozanski; Yiming Zhong; Amy S Ruppert; David Lucas; Katie Williams; Weiqiang Zhao; Laura Rassenti; Emanuela Ghia; Thomas J Kipps; Rose Mantel; Jeffrey Jones; Joseph Flynn; Kami Maddocks; Susan O'Brien; Richard R Furman; Danelle F James; Fong Clow; Gerard Lozanski; Amy J Johnson; John C Byrd
Journal:  Blood       Date:  2014-01-10       Impact factor: 22.113

6.  The novel receptor tyrosine kinase Axl is constitutively active in B-cell chronic lymphocytic leukemia and acts as a docking site of nonreceptor kinases: implications for therapy.

Authors:  Asish K Ghosh; Charla Secreto; Justin Boysen; Traci Sassoon; Tait D Shanafelt; Debabrata Mukhopadhyay; Neil E Kay
Journal:  Blood       Date:  2010-12-06       Impact factor: 22.113

7.  Targeted Axl Inhibition Primes Chronic Lymphocytic Leukemia B Cells to Apoptosis and Shows Synergistic/Additive Effects in Combination with BTK Inhibitors.

Authors:  Sutapa Sinha; Justin Boysen; Michael Nelson; Charla Secreto; Steven L Warner; David J Bearss; Connie Lesnick; Tait D Shanafelt; Neil E Kay; Asish K Ghosh
Journal:  Clin Cancer Res       Date:  2015-02-11       Impact factor: 12.531

8.  The tumor suppressor axis p53/miR-34a regulates Axl expression in B-cell chronic lymphocytic leukemia: implications for therapy in p53-defective CLL patients.

Authors:  J Boysen; S Sinha; T Price-Troska; S L Warner; D J Bearss; D Viswanatha; T D Shanafelt; N E Kay; A K Ghosh
Journal:  Leukemia       Date:  2013-10-18       Impact factor: 11.528

9.  Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies.

Authors:  Ranjana H Advani; Joseph J Buggy; Jeff P Sharman; Sonali M Smith; Thomas E Boyd; Barbara Grant; Kathryn S Kolibaba; Richard R Furman; Sara Rodriguez; Betty Y Chang; Juthamas Sukbuntherng; Raquel Izumi; Ahmed Hamdy; Eric Hedrick; Nathan H Fowler
Journal:  J Clin Oncol       Date:  2012-10-08       Impact factor: 44.544

10.  The splicing modulator sudemycin induces a specific antitumor response and cooperates with ibrutinib in chronic lymphocytic leukemia.

Authors:  Sílvia Xargay-Torrent; Mónica López-Guerra; Laia Rosich; Arnau Montraveta; Jocabed Roldán; Vanina Rodríguez; Neus Villamor; Marta Aymerich; Chandraiah Lagisetti; Thomas R Webb; Carlos López-Otín; Elias Campo; Dolors Colomer
Journal:  Oncotarget       Date:  2015-09-08
View more
  8 in total

Review 1.  Therapeutic Targeting of the Gas6/Axl Signaling Pathway in Cancer.

Authors:  Mai Tanaka; Dietmar W Siemann
Journal:  Int J Mol Sci       Date:  2021-09-15       Impact factor: 6.208

Review 2.  Drugging the efferocytosis process: concepts and opportunities.

Authors:  Parul Mehrotra; Kodi S Ravichandran
Journal:  Nat Rev Drug Discov       Date:  2022-06-01       Impact factor: 112.288

3.  Pharmacokinetic and pharmacodynamic evaluation of ibrutinib for the treatment of chronic lymphocytic leukemia: rationale for lower doses.

Authors:  Prithviraj Bose; Varsha V Gandhi; Michael J Keating
Journal:  Expert Opin Drug Metab Toxicol       Date:  2016-10-11       Impact factor: 4.481

Review 4.  Targeting the TAM Receptors in Leukemia.

Authors:  Madeline G Huey; Katherine A Minson; H Shelton Earp; Deborah DeRyckere; Douglas K Graham
Journal:  Cancers (Basel)       Date:  2016-11-08       Impact factor: 6.639

Review 5.  AXL receptor tyrosine kinase as a promising anti-cancer approach: functions, molecular mechanisms and clinical applications.

Authors:  Chenjing Zhu; Yuquan Wei; Xiawei Wei
Journal:  Mol Cancer       Date:  2019-11-04       Impact factor: 27.401

Review 6.  AXL Receptor Tyrosine Kinase as a Therapeutic Target in Hematological Malignancies: Focus on Multiple Myeloma.

Authors:  Siyang Yan; Niels Vandewalle; Nathan De Beule; Sylvia Faict; Ken Maes; Elke De Bruyne; Eline Menu; Karin Vanderkerken; Kim De Veirman
Journal:  Cancers (Basel)       Date:  2019-11-05       Impact factor: 6.639

Review 7.  The Development of AXL Inhibitors in Lung Cancer: Recent Progress and Challenges.

Authors:  Yun Beom Sang; Joo-Hang Kim; Chang-Gon Kim; Min Hee Hong; Hye Ryun Kim; Byoung Chul Cho; Sun Min Lim
Journal:  Front Oncol       Date:  2022-03-03       Impact factor: 6.244

Review 8.  Role of Bruton's tyrosine kinase in B cells and malignancies.

Authors:  Simar Pal Singh; Floris Dammeijer; Rudi W Hendriks
Journal:  Mol Cancer       Date:  2018-02-19       Impact factor: 27.401
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.